Updates in pharmacotherapy of heart failure with reduced ejection fraction.
Ontology highlight
ABSTRACT: Heart failure is a common entity encountered in healthcare with a vast socioeconomic impact. Recent advances in pharmacotherapy have led to the development of novel therapies with mortality benefits, improvement in heart failure symptoms and hospitalizations. This article is intended to explore those newer pharmacotherapies and summarize the evidence behind guideline directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF). It has been several years since any significant advances in pharmacotherapy of heart failure have resulted in survival benefit. Angiotensin-neprilysin inhibitors through the PARADIGM-HF and PIONEER-HF trials have shown mortality benefits and a reduction in heart failure hospitalizations and are considered landmark trials in heart failure.
SUBMITTER: Espinoza C
PROVIDER: S-EPMC8039644 | biostudies-literature | 2021 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA